Who
Nancy Ryan Gray
Director
Company insider
Files Form 4 as: Director, Ligand Pharmaceuticals.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.4M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 18 Aug 2017
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,556 at $0.00 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,015 at $0.00 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $235K3,556 at $66.19 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $731K3,556 at $205.45 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $222K3,015 at $73.57 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $619K3,015 at $205.45 | filing |
| 6 Jun 2025filed 10 Jun 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,783 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,209 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,444 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,252 at $0.00 | filing |
| 9 May 2024filed 17 May 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $78K934 at $83.20 | filing |
| 9 Jun 2023filed 13 Jun 2023 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,461 at $0.00 | filing |
| 9 Jun 2023filed 13 Jun 2023 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,142 at $0.00 | filing |
| 22 Dec 2022filed 27 Dec 2022 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,050 at $0.00 | filing |
| 10 Jun 2022filed 13 Jun 2022 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,340 at $0.00 | filing |
| 10 Jun 2022filed 13 Jun 2022 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,004 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.